In this video, health care analyst David Williamson discusses Vertex Pharmaceuticals' recent third-quarter results, breaking down the company's surprising loss and estimate miss, along with the future of its lead drug, Incivek. Watch and find out what investors should take away from these disappointing results.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.